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Abstract	
Background:	Over	 recent	 years	 genetic	 testing	 for	 germline	mutations	 in	BRCA1/BRCA2	 has	become	more	
readily	 available	 because	 of	 technological	 advances	 and	 reducing	 costs.	 The	 Genetic	 Testing	 in	 Epithelial	
Ovarian	 Cancer	 (GTEOC)	 Study	 explored	 the	 feasibility	 and	 acceptability	 of	 offering	 genetic	 testing	 to	 all	
women	recently	diagnosed	with	epithelial	ovarian	cancer	(EOC).	
Methods:	From	1st	July	2013	to	30th	June	2015	women	newly	diagnosed	with	EOC	were	recruited	through	six	
sites	 in	 East	 Anglia,	 UK.	 Eligibility	 was	 irrespective	 of	 patient	 age	 and	 family	 history	 of	 cancer.	 The	
psychosocial	 arm	 of	 the	 study	 utilised	 self-report,	 psychometrically	 validated	 questionnaires	 (Depression	
Anxiety	and	Stress	Scale,	DASS-21;	Impact	of	Event	Scale,	IES)	and	cost	analysis	was	performed.	
Results:	 232	women	were	 recruited	 and	 18	mutations	were	 detected	 (12	 in	BRCA1,	 6	 in	BRCA2)	 giving	 a	
mutation	yield	of	8%	which	increases	to	12%	in	unselected	women	<70	years	(17/146)	and	1%	in	unselected	
women	>70	years	(1/86).	IES	and	DASS-21	scores	in	response	to	genetic	testing	were	significantly	lower	than	
equivalent	scores	in	response	to	cancer	diagnosis	(p<.001).	Correlation	tests	indicated	that	whilst	older	age	is	
a	protective	factor	against	any	traumatic	impacts	of	genetic	testing,	no	significant	correlation	exists	between	
age	and	distress	outcomes.	
Conclusion:	The	mutation	yield	in	unselected	women	diagnosed	with	EOC	from	a	heterogeneous	population	
with	no	 founder	mutations	was	8%	 in	all	ages	and	12%	 in	women	under	70.	Unselected	genetic	 testing	 in	
women	with	EOC	was	acceptable	to	patients	and	is	potentially	less	resource-intensive	than	current	standard	
practice.		
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Introduction	
Approximately	1.5%	of	women	will	be	diagnosed	with	epithelial	ovarian	cancer	(EOC)	in	their	lifetime	and,	as	
a	 result	 of	 the	 relatively	 poor	 prognosis,	 it	 is	 the	 fifth	 commonest	 cause	 of	 cancer-related	 mortality	 in	
females.	In	the	mid	1990s	germline	mutations	in	the	BRCA1	and	BRCA2	genes	were	identified	in	families	with	
hereditary	breast	and	ovarian	cancer	and	testing	for	these	genes	is	available	through	the	NHS	genetic	service	
providing	that	the	family	history	is	sufficiently	strong	to	instigate	a	referral	(NICE	guideline	CG41).	A	woman	
with	a	mutation	in	the	BRCA1	gene	has	a	40-60%	lifetime	risk	of	developing	EOC[1].	For	BRCA2	the	lifetime	
risk	is	lower	at	10–30%,	but	this	is	still	around	10-fold	elevated	compared	to	the	general	population	risk.	At	
present	there	is	no	proven	clinical	screening	for	EOC	[2]	and	unaffected	women	with	completed	families	who	
carry	BRCA1/BRCA2	mutations	 typically	 elect	 to	 have	 a	 prophylactic	 bilateral	 salpingo-oophorectomy	 that	
reduces	the	risk	of	EOC	by	80–96%	[3-5].	The	prevalence	of	BRCA1/BRCA2	mutations	in	unselected	women	
with	ovarian	cancers	ranges	from	8	to	22%[6-10],	and	this	variation	can	in	part	be	explained	by	the	presence	
or	absence	of	 founder	mutations	 in	 the	study	populations.	 In	one	study	of	1,342	unselected	patients	with	
invasive	 ovarian	 cancer	 161	BRCA1/BRCA2	 carriers	 were	 identified	 in	 1,038	women	 diagnosed	with	 high-
grade	 serous	 (HGSOC)	 or	 endometrioid	 (EC)	 ovarian	 cancer	 (overall	 frequency	 15.5%)	 confirming	 that	
inherited	mutations	 in	 these	 genes	 account	 for	 a	 significant	minority	 of	 all	 ovarian	 cancer	 cases	 [9].	 The	
frequency	of	mutations	was	highest	 in	 the	HGSOC	group	(135	carriers,	18%)	but	also	significant	 in	women	
with	EC	(26	carriers,	9%).	Family	history	of	breast	or	ovarian	cancer	was	the	best	predictor	of	carrier	status	
(33%	 had	 a	 first	 degree	 relative	with	 breast	 or	 ovarian	 cancer)	 but	 7.9%	 of	 all	 carriers	 had	 no	 significant	
family	history.	
Genetic	 testing	 for	mutations	 in	BRCA1/BRCA2	was	 introduced	 into	 clinical	 practice	 in	 the	 late	 1990s	 but	
because	of	the	cost	and	technical	complexity	of	testing	it	was	initially	limited	to	those	cases	where	there	was	
a	 greater	 than	 20%	 probability	 of	 detecting	 a	 mutation	 (NICE	 guideline	 CG41),	 with	 the	 threshold	 being	
lowered	 to	 10%	 since	 2013	 (NICE	 guideline	 CG164).	 Various	 models,	 such	 as	 BOADICEA	 [11]	 and	 the	
Manchester	 score	 [12],	 have	 been	 developed	 to	 estimate	 the	 probability	 of	 finding	 a	 BRCA1/BRCA2	
mutation.	 While	 these	 are	 extensively	 used	 in	 Clinical	 Genetics	 centres,	 they	 have	 in	 general	 not	 been	
incorporated	 into	 routine	 clinical	 practice	 outside	 of	 Clinical	 Genetics.	 Despite	 increasing	 awareness	 of	
BRCA1/BRCA2	in	the	medical	community,	referral	rates	vary	considerably	and	many	women	are	not	referred	
for	a	genetic	assessment;	only	20%	of	 the	cohort	studied	by	Zhang	et	al.	had	previously	been	referred	 for	
genetic	testing	[13]	and	as	the	referred	group	only	contained	60%	of	all	mutation	carriers,	it	meant	that	40%	
of	mutation	carriers	were	missed.	If	more	mutation	carriers	can	be	identified	this	will	increase	the	numbers	
of	 families	where	cascade	genetic	 testing	can	be	offered	so	that	more	 female	relatives	at	high	risk	of	EOC	
and	breast	cancer	can	be	identified,	counselled	and	managed	appropriately.		
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BRCA1/BRCA2	 mutation	 carriers	 with	 EOC	 have	 a	 better	 short	 term	 survival	 compared	 with	 non-
BRCA1/BRCA2	women	[14]	and	there	is	emerging	evidence	that	BRCA2	mutation	status	in	particular	is	likely	
to	 be	 an	 important	 prognostic	 and	 predictive	 marker	 in	 EOC	 with	 a	 significantly	 higher	 primary	
chemotherapy	sensitivity	rate	[14	15]	although	the	survival	difference	becomes	less	apparent	over	time	[16].	
It	 also	appears	 that	BRCA1/BRCA2	mutation	 status	provides	predictive	 information	 regarding	 likelihood	of	
response	to	PARP	inhibitors	[17	18].		
In	 this	 study	 we	 explored	 the	 acceptability	 and	 feasibility	 of	 universal	 testing	 without	 pre-test	 genetic	
counselling	 BRCA1/BRCA2	 in	 an	 unselected	 population	 of	 women	 who	 were	 within	 12	 months	 of	 being	
diagnosed	with	EOC.	We	used	established	metrics	(the	Depression	Anxiety	and	Stress	Scale,	DASS-21	and	the	
Impact	 of	 Event	 Scale,	 IES)	 to	 assess	 psychological	 distress,	 tailored	 questionnaires	 to	 gauge	 acceptability	
and	undertook	a	detailed	cost	analysis	to	compare	resource	use	with	the	standard	genetic	testing	model.	
	
Methods	
Patient	eligibility	Patients	were	eligible	 if	 they	were	over	18	years	old	and	had	been	diagnosed	with	high-
grade	 serous	 or	 endometrioid	 epithelial	 ovarian	 cancer	 within	 the	 last	 12	 months.	 Other	 ovarian	 cancer	
subtypes	including	low	grade	tumours	were	excluded	as	they	are	not	part	of	the	BRCA1/BRCA2	phenotype	
[9].	The	study	had	full	ethical	approval	(REC12/EE/0433).	
Patient	recruitment:	Women	were	recruited	though	six	NHS	hospitals	of	different	sizes	ranging	from	smaller	
district	 general	 hospitals	 to	 large	 regional	 centres	 (Figure	 1).	 All	 women	 with	 ovarian	 cancer	 in	 the	 East	
Anglia	region	are	managed	in	these	six	institutions,	which	allows	for	near-complete	ascertainment	of	cases.	
Eligible	 women	 were	 approached	 by	 their	 treating	 clinician	 or	 specialist	 nurse.	 If	 the	 patient	 expressed	
interest	in	the	study,	information	about	the	patient	was	passed	to	the	study	coordinator	who	provided	the	
patient	with	 detailed	 information	 about	 the	 study	 and	obtained	 informed	 consent.	 Additionally	 the	 letter	
was	sent	to	the	patient	to	collect	her	demographic	details	and	family	history	(Figure	2).	No	formal	genetic	
counselling	was	given	prior	to	testing.		
Genetic	 counselling	 and	 testing	 process:	 BRCA1/BRCA2	 testing	 was	 performed	 in	 the	 clinically	 accredited	
laboratory	 of	 the	 East	 Anglian	 Genetics	 Service	 by	 Next	 Generation	 Sequencing	 and	 MLPA.	 If	 a	 gene	
mutation	was	 identified	 the	 patient,	 her	 general	 practitioner	 and	 her	 treating	 clinician	were	 informed	 by	
letter	 from	 the	 study	 team	 and	 a	 referral	 to	 the	 NHS	 clinical	 genetics	 service	 was	 requested	 for	 genetic	
counselling	 and	 cascade	 testing	 of	 other	 at-risk	 family	members.	Where	 variants	 of	 unknown	 significance	
(VUS)	were	identified	these	were	also	fed	back	to	the	participant,	GP	and	her	clinician	by	letter,	and	again	a	
referral	 for	 genetic	 counselling	 was	 requested	 (Figure	 2).	 	 	 Only	 those	 women	 with	 mutations	 or	 VUS	
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received	 formal	 post-test	 genetic	 counselling	 via	 the	 standard	 clinical	 service.	 All	 family	 histories	 were	
assessed	by	a	Geneticist	when	the	mutation	report	was	generated.	 If	 there	was	a	clinically	 relevant	 family	
history	that	met	standard	referral	criteria	in	women	with	no	mutations	this	was	noted	in	the	results	letter	to	
the	participant	with	advice	to	seek	a	genetics	referral.	
	
Cost-analysis:	In	order	to	determine	the	resource	implications	of	offering	universal	BRCA1/BRCA2	testing	in	
an	unselected	population	of	women	within	12	months	of	being	diagnosed	with	EOC	we	undertook	a	cost-
analysis.	We	mapped	both	the	existing	(current	standard)	referral	and	testing	pathway	(Figure	S1)	and	the	
new	proposed	referral	and	testing	pathway	(Figure	S2).	Once	these	pathways	were	mapped,	we	defined	the	
service	activities	and	determined	 the	 resources	 required	 to	undertake	 these	activities	using	a	 ‘bottom-up’	
micro-costing	approach	in	order	to	calculate	the	overall	cost	for	both	pathways.	Costs	are	reported	in	2015	
UK	£	and	from	the	perspective	of	the	clinical	genetics	service	from	referral	for	genetic	testing	to	diagnostic	
BRCA1/BRCA2	 test	outcome	of	the	 index	case.	Market	prices	taken	from	the	NHS	test	directory	hosted	on	
the	UKGTN	website	(http://ukgtn.nhs.uk)	were	used	for	the	actual	genetic	testing	of	BRCA1/BRCA2.	The	cost	
of	staff	 (administrators	and	clinical	staff)	were	obtained	from	both	the	NHS	agenda	for	change	(2015)	and	
the	Personal	Social	Services	Research	Unit	(PSSRU)	reference	costs	for	2014/2015.	We	used	the	mid-point	of	
each	grade	and	 included	National	 Insurance,	 superannuation	and	overhead	costs	 if	 they	were	not	already	
included.	All	cost	data	collected	are	reported	in	Table	S1.	Here	we	report	the	average	testing	pathway	cost	
per	BRCA1/BRCA2	mutation	 identified,	 the	average	 testing	pathway	cost	per	genetic	 test	offered,	and	 the	
overall	budget	required	for	the	232	EOC	patients	eligible	for	inclusion	within	the	GTEOC	study.	
The	main	(base	case)	analysis	assumes	that	 in	addition	to	those	meeting	the	Manchester	score	for	genetic	
testing	 (n=63	of	 the	232	EOC	patients),	half	 (50%)	of	 those	affected	by	epithelial	ovarian	cancer	were	also	
referred	 through	 to	 the	 cancer	 genetics	 service	 to	 have	 their	 family	 history	 checked	 before	 determining	
whether	 they	 would	 have	 genetic	 testing.	 The	 base	 case	 analysis	 does	 not	 have	 an	 age	 cut-off	 and	 no	
discount	rate	has	been	applied	given	that	all	patients	would	expect	to	receive	the	result	of	their	genetic	test	
within	a	year.	
Cost-analysis	sensitivity	analysis:	Sensitivity	analyses	allow	 insight	 into	which	assumptions	or	 limitations	to	
the	 data	 included	 are	 important	 to	 the	 overall	 result	 or	 conclusion	 drawn	 from	 the	 analysis.	 A	 pragmatic	
approach	 to	conducting	one-way	sensitivity	analyses	was	undertaken	and	 included	varying	 the	cost	of	 the	
genetic	test	(assay	price	in	both	pathways),	percentage	of	patients	referred	to	the	cancer	genetics	service	in	
the	existing	current	testing	pathway	(from	0%	of	patients	not	meeting	the	Manchester	score	to	100%	i.e.	all	
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patients	offered	 initial	appointment	 in	cancer	genetics	 service),	and	 limiting	 the	genetic	 testing	within	 the	
GTEOC	testing	pathway	to	women	under	70.		
Psychological	impact	and	acceptability	analysis:	All	participants	who	underwent	genetic	testing	were	asked	
to	 complete	 a	 short,	 self-report	 questionnaire	 which	 was	 sent	 to	 them	 by	 post	 to	 limit	 intrusion.	 	 This	
included	 the	 Depression,	 Anxiety	 and	 Stress	 Scale	 (DASS-21)[19]	 and	 the	 Impact	 of	 Event	 Scale	 (IES)[20].		
Each	scale	was	presented	twice:	once	anchored	to	the	psychological	 impact	of	diagnosis	of	ovarian	cancer,	
and	a	second	time	anchored	to	the	psychological	impact	of	the	genetic	test.		A	further	twelve	study-specific	
questions	assessed	the	acceptability	of	this	method	of	genetic	testing.	
Results	
A	total	of	232	of	281	eligible	women	(83%)	were	consented	to	participate	and	tested	over	the	study	period.	
Almost	 all	 (98%)	 participants	 reported	 their	 ethnicity	 as	 white	 British,	 in	 keeping	 with	 the	 demographic	
profile	of	the	region	(Table	1).	The	mean	age	of	the	participants	was	63	years	(range	30-90	years)	and	two-
thirds	of	the	participants	were	60	years	or	older	which	is	consistent	with	the	observed	age	profile	in	women	
diagnosed	with	EOC.	One	hundred	and	ninety	one	participants	(82%)	had	high-grade	serous	ovarian	cancer,	
20	 (9%)	 had	 endometrioid	OC,	 15	 (6%)	 had	 unspecified	 or	 poorly	 differentiated	 adenocarcinomas	 and	 six	
(2.5%)	were	mixed	types.	The	median	time	from	consent	to	results	delivered	was	46	working	days	(range	15-
117	 days).	 The	mean	 time	 from	 sample	 receipt	 to	 results	 delivered	was	 39	working	 days	 (range	 11-	 111	
days).	 Overall,	 175	 women	 (75%)	 had	 stage	 III	 or	 IV	 disease.	 Educational	 levels	 were	 available	 on	 166	
participants	 (72%)	 and	 in	 this	 group	 of	 women	 100	 	 (60%)	 had	 completed	 secondary	 education	 only,	 37	
(22%)	had	completed	a	diploma	and	25	(15%)	were	educated	to	degree	level	(Table	1).		
Eighteen	 BRCA1/BRCA2	 predicted	 loss-of-function	 mutations	 were	 detected	 (12	 in	 BRCA1,	 six	 in	 BRCA2)	
giving	an	overall	prevalence	of	8%	(Table	2).	None	of	the	mutations	were	common	founder	mutations	seen	
in	other	populations	(Table	S2)[21].	The	mean	age	of	mutation	carriers	was	50	years	(range	40-75	years)	with	
a	mutation	prevalence	of	12%	in	women	under	70	years	of	age	(17/146)	and	1%	in	unselected	women	70	or	
older	(1/86).		
In	women	under	70	years	of	age	with	a	positive	family	history	(affected	first-	or	second-degree	relative)	the	
mutation	prevalence	17%	(13/77),	but	one	quarter	of	the	carriers	in	this	age	group	had	no	family	history.		Six	
mutation	carriers	had	a	previous	personal	history	of	breast	cancer	(Table	2).	All	twelve	BRCA1	and	five	of	the	
BRCA2	mutation	positive	cases	had	high-grade	serous	ovarian	cancer	(Table	2).	The	other	BRCA2	mutation	
positive	 case	 had	 a	 high-grade	 adenocarcinoma	 with	 features	 suggestive	 of	 an	 endometrioid	
adenocarcinoma.	Seventeen	VUS	were	detected	in	15	patients,	14	in	BRCA1	and	3	in	BRCA2.	
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All	12	BRCA1	and	five	of	the	BRCA2	mutation	positive	cases	had	serous	papillary	type	ovarian	cancer	(Table	
2).	One	of	the	BRCA2	mutation	positive	cases	had	high	grade	adenocarcinoma	with	features	 in	favour	of	a	
grade	3	endometrioid	adenocarcinoma.		
Psychological	 impact:	 173	 questionnaires	 were	 returned	 (75%).	 IES	 (cognitive	 intrusion	 i.e.	 unwanted	
intrusive	 thoughts	 about	 the	 phenomenon,	 avoidance	 behaviour,	 hyperarousal	 i.e.	 a	 state	 of	
increased	psychological	and	 physiological	 tension)	 and	 DASS-21	 (depression,	 anxiety	 and	 stress)	 scores	 in	
response	to	genetic	testing	were	significantly	 lower	than	equivalent	scores	in	response	to	cancer	diagnosis	
(Wilcoxon	Signed	Rank	tests	Z-score	range	=	-6.174	to	-8.852;	all	p<.001).	Essentially,	having	the	genetic	test	
did	not	 increase	distress	or	psychological	 traumatic	 response	beyond	 that	 already	being	experienced	as	 a	
result	of	the	cancer	diagnosis	itself.	Younger	participants	found	the	test	to	lead	to	more	intrusive	thoughts	
(IES	 intrusion	 r=-.172,	 p=.026),	 and	 significantly	more	 stress	 (DASS	 stress	 r=.162,	p=.014).	 	 There	were	 no	
significant	differences	based	on	age	 for	 IES	avoidance	 IES	hyperarousal,	DASS	anxiety	or	DASS	depression.	
There	 were	 no	 significant	 differences	 on	 any	 IES	 or	 DASS	 subscale	 by	 education	 level,	 cancer	 stage,	
Manchester	 Score	 or	 previous	 cancer	 history.	 A	 significant	 difference	 was	 found	 in	 cognitive	 avoidance	
scores	 based	 on	 categorisation	 of	 BRCA	 mutation	 status	 (p=.036),	 with	 highest	mean	 scores	 reported	 by	
those	with	a	BRCA1	or	BRCA2	mutation.		The	study	population	was	not	sufficiently	heterogeneous	to	explore	
any	differences	based	on	either	ethnicity	or	country	of	birth.		
Acceptability	of	the	test:	High	 levels	of	acceptability	were	reported	(Table	3)	and	participants	felt	they	had	
enough	information	and	time	to	proceed	with	genetic	testing.	Most	women	talked	to	their	family	about	the	
test	 and	 felt	 that	 the	 test	 gave	 them	a	better	understanding	of	 their	 family’s	 risk.	 The	widest	 variation	 in	
scores	 related	 to	 the	 perceived	 level	 of	 ease	with	which	 participants	made	 the	 decision	 to	 proceed	with	
genetic	testing.	
Cost	 analysis:	 For	 the	 base	 case	 analysis,	 the	 overall	 budget,	 the	 average	 patient	 pathway	 cost	 per	
BRCA1/BRCA2	 mutation	 positive,	 and	 the	 average	 patient	 pathway	 cost	 per	 test	 offered	 for	 the	 current	
pathway	 were	 £142,702,	 £11,892,	 and	 £2,265,	 respectively.	 For	 the	 GTEOC	 patient	 pathway,	 these	 costs	
were	 £253,617,	 £14,919	 and	 £1,093,	 respectively	 (Table	 S2).	 The	 larger	 budget	 for	 the	 GTEOC	 patient	
pathway	 represents	 the	 increased	 cost	 due	 to	 a	 significantly	 greater	 number	of	 genetic	 tests	 undertaken.	
When	the	cost	of	the	genetic	testing	is	removed	from	the	cost	of	the	patient	pathway,	the	budget	for	GTEOC	
patient	 pathway	 is	 lower	 (£56,166	 versus	 £88,633	 for	 the	 current	 patient	 pathway).	 The	 non-genetic	 test	
related	costs	within	the	GTEOC	patient	pathway	account	for	approximately	22%	of	the	budget	compared	to	
62%	 for	 the	 current	patient	pathway	within	 the	base-case	analysis.	 The	average	patient	pathway	cost	per	
patient	without	 the	 genetic	 testing	 for	 the	GTEOC	 and	 the	 current	 testing	 patient	 pathway	 are	 £243	 and	
£383,	respectively.	
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Sensitivity	analysis:	The	results	of	the	sensitivity	analysis	show	that	changing	the	cost	of	the	genetic	test	has	
a	 large	 impact	 on	 the	 budget,	 the	 average	 patient	 pathway	 cost	 per	BRCA1/BRCA2	 positive	 and	 also	 the	
average	 testing	pathway	cost	per	 test	offered	 for	both	pathways	 (Table	S2).	 If	 the	cost	of	 the	genetic	 test	
were	to	come	down	to	£190,	the	budget	required	for	the	GTEOC	pathway	would	be	the	same	as	the	current	
pathway	ceteris	paribus	 in	 the	base	case	analysis.	Changing	 the	number	of	women	 referred	 to	 the	cancer	
genetics	service	impacts	on	the	budget	required	for	the	existing	pathway.	Implementing	the	age	cut-off	for	
eligibility	of	genetic	testing	in	the	GTEOC	pathway	has	a	large	impact	on	the	budget	required	to	test	the	232	
eligible	women.	Even	with	a	genetic	test	price	of	£650	(the	current	price	of	a	clinical	exome),	implementing	
the	 age	 cut-off	within	 the	GTEOC	patient	 pathway	would	 lead	 to	 a	 lower	 budget	 for	 the	GTEOC	pathway	
(£121,229	versus	£130,102	for	the	current	patient	pathway).	
Conclusions	
The	primary	objective	of	the	study	was	to	determine	the	feasibility,	acceptability	and	cost-effectiveness	of	Is	
screening	all	newly	diagnosed	women	with	EOC	for	BRCA1/BRCA2	mutations	by	determining	the	mutation	
prevalence,	 calculating	 cost	 per	 gene	 mutation	 detected	 and	 assessing	 psychological	 impact	 based	 on	
questionnaire	responses	and	qualitative	interviews.	
The	 mutation	 prevalence	 in	 an	 unselected	 cohort	 of	 women	 diagnosed	 with	 EOC	 from	 a	 heterogeneous	
population	with	no	founder	mutations	was	8%	in	all	ages	and	12%	in	women	under	70	years.	This	is	similar	
to	that	reported	in	a	combined	study	of	two	large	case-control	OC	series	(one	of	which	included	cases	from	
the	East	Anglia	region)[8],	but	lower	than	that	the	frequency	of	15%	reported	a	recent	study	by	Norquist	et	
al.	[10].	These	differences	are	likely	to	be	partly	explained	by	the	presence	or	absence	of	founder	mutations	
in	the	test	populations	as	13%	of	all	the	BRCA1/BRCA2	mutations	identified	in	the	Norquist	study	were	those	
commonly	found	in	individuals	of	Ashkenazi	Jewish	descent.	
The	 cost-analysis	 undertaken	 here	 provides	 some	 insight	 into	 the	 potential	 delivery	 of	 BRCA1/2	 genetic	
testing	in	a	cohort	of	women	diagnosed	with	EOC.	The	burden	of	cost	in	the	provision	of	genetic	testing	lies	
in	 the	 provision	 of	 diagnostic	 testing	 for	 the	 current	 patient	 pathway	 (62%	 of	 costs	 are	 non-genetic	 test	
related)	whereas	with	 the	GTEOC	pathway	 the	burden	 lies	with	 the	cost	of	 the	genetic	 testing	 itself	 (only	
22%	of	costs	were	non-genetic	test	related).	Furthermore,	given	the	high	price	of	genetic	testing	used	within	
the	base-case,	when	a	more	realistic	current	day	price	is	included	as	a	sensitivity	analysis	and	is	coupled	with	
the	use	of	an	age	cut-off,	 the	GTEOC	patient	testing	pathway	 is	 likely	cost-saving	compared	to	the	current	
testing	pathway	 for	 this	patient	 cohort.	However,	 a	 clear	 limitation	of	 this	 analysis	 is	 the	exclusion	of	 the	
costs	 involved	in	the	clinical	management	of	these	patients	as	these	costs	are	 likely	to	be	significant	when	
cascade	testing	is	also	included	into	the	‘patient’	pathway.	
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Based	 on	 our	 findings	we	would	 recommend	 offering	 testing	 to	 all	 women	 under	 70	 years	 of	 age	 as	 the	
mutation	 prevalence	 would	 be	 above	 the	 current	 threshold	 of	 10%	 used	 for	 eligibility	 for	 testing	 breast	
cancer	families	in	the	UK	(NICE	CG164).	This	age	cut-off	would	also	improve	the	mutation:	VUS	ratio	from	1:1	
to	2:1.	 	By	not	testing	those	over	70	years	 it	 is	possible	to	reduce	the	number	of	tests	by	around	37%	and	
miss	only	6%	of	all	mutations.	Indeed,	in	this	study	both	women	over	the	age	of	70	years	with	mutations	had	
a	 family	 history	 of	 breast	 or	 ovarian	 cancer.	 No	mutation	 carriers	 would	 have	 been	missed	 by	 using	 the	
criteria	of	1)	age	under	70	years,	or	2)	70	years	and	over	with	a	previous	history	of	breast	cancer	or	history	of	
breast	or	ovarian	cancer	in	a	first	degree	relative.			
A	key	question	of	the	GTEOC	study	was	whether	outcome	of	the	genetic	test	affects	IES	or	DASS-21	scores.	
Our	study	investigated	the	hypothesis	that	psychological	response	to	the	genetic	test	may	lead	to	increased	
distress	beyond	that	of	the	cancer	diagnosis	itself.	 	Methodologically,	this	was	difficult	to	test	and	we	used	
the	 approach	 of	 including	 each	 psychological	measure	 twice	 (with	 different	 anchoring)	 to	 let	 participants	
distinguish	their	psychological	responses	to	the	genetic	test	from	their	psychological	response	to	the	cancer	
diagnosis	 itself.	 	 That	 participants	 responded	 differently	 to	 identical	 questions	 anchored	 to	 each	 event	
suggests	that	this	is	a	useful	methodology;	mean	ratings	on	all	subscales	of	both	the	IES	and	the	DASS	were	
significantly	higher	for	diagnosis	than	for	the	genetic	test,	consistent	with	previous	findings	in	breast	cancer	
patients	[22].	We	also	investigated	whether	the	psychological	response	to	the	genetic	test	would	be	affected	
by	 participant	 demographics.	 	 Correlation	 analyses	 indicated	 no	 significant	 effects	 of	 age	 on	 depression,	
anxiety	cognitive	avoidance	or	hyperarousal;	significant	negative	correlations	indicate	an	inverse	relationship	
between	 younger	 age	 and	 higher	 levels	 of	 perceived	 stress	 and	 cognitive	 intrusion.	 	 This	 result	 fits	 the	
pattern	 of	 broader	 literature	 on	 the	 psychological	 impact	 of	 cancer	 diagnosis	 and	 treatment,	 whereby	
adjustment	is	typically	worse	in	those	diagnosed	at	a	younger	age	[23].	Those	later	found	to	have	a	genetic	
mutation	scored	significantly	higher	on	cognitive	avoidance,	but	no	differences	in	other	subscales	assessed	
were	identified.		Self-reported	acceptability	data	were	favourable	and	support	the	value	and	acceptability	of	
the	testing	procedure	in	this	sample.	
Genetic	counselling	protocols	have	evolved	from	a	paradigm	initially	developed	in	the	context	of	predictive	
testing	 for	Huntington’s	disease	 (HD).	Due	to	concerns	about	 the	negative	and	potentially	grave	 impact	of	
receiving	 a	 molecular	 diagnosis	 of	 HD,	 a	 protocol	 involving	 two	 face-to-face	 pre-test	 appointments	 and	
follow	up	was	developed	[24].	It	has	long	been	thought	that	this	level	of	support	may	not	be	required	in	the	
diagnostic	setting[25]	and	with	the	advent	of	targeted	therapies	the	need	for	systematic	genetic	testing	has	
become	more	pressing,	but	current	pathways	are	not	designed	for	high	volume	testing.	One	solution	would	
be	to	devolve	genetic	testing	completely	to	the	oncologists	but	this	approach	fails	to	take	advantage	of	the	
comprehensive	 clinical	 genetic	 networks	 that	 exist	 in	 most	 countries.	 There	 are	 also	 other	 concerns	
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regarding	 this	 approach;	 the	 interpretation	 of	 VUS	may	 not	 be	 adequate[26],	 and	 cascade	 testing	within	
families	may	not	occur	(Figure	3).			
A	unique	strength	of	this	study	is	the	near	complete	ascertainment	of	women	with	ovarian	cancer	recruited	
through	both	secondary	and	tertiary	referral	centres	in	a	clearly	defined	geographical	region	which	is	highly	
representative	of	clinical	services	throughout	the	UK	and	internationally.	These	findings	are	therefore	likely	
to	be	widely	applicable,	and	similar	novel	approaches	have	been	trialled	in	other	countries	such	as	Norway	
[7]		and	The	Netherlands	[27]	Even	though	overall	numbers	tested	are	relatively	small,	the	participation	rate	
was	 high	 and	 the	 mutation	 yield	 is	 consistent	 with	 those	 reported	 in	 other	 studies	 in	 heterogeneous	
populations	lacking	founder	mutations.	One	weakness	is	the	lack	of	ethnic	diversity	in	the	study	participants	
which	 reflects	 the	 relative	homogeneity	of	 the	East	Anglian	population	 (91%	white	Caucasian	 for	all	 ages;	
Office	for	National	Statistics,	2011	Census	data	from	KS201EW).	Further	studies	would	be	required	to	assess	
acceptability	in	more	ethnically	diverse	regions.		
These	 results	 show	 universal	 genetic	 testing	 in	 women	with	 a	 diagnosis	 of	 EOC	 to	 be	 an	 acceptable	 and	
sensitive	 procedure:	 	 these	 women	 have	 much	 emotional	 work	 to	 do	 as	 they	 confront	 their	 diagnosis,	
mortality	 and	 the	 impact	 on	 family	 members.	 Our	 data	 show	 that	 this	 type	 of	 genetic	 testing	 does	 not	
increase	 distress	 or	 traumatic	 response	 significantly	 beyond	 that	 already	 experienced	 following	 cancer	
diagnosis.	 	Older	age	was	a	protective	 factor	against	 traumatic	 response,	but	not	distress.	Comprehensive	
case-based	genetic	testing	appears	to	be	acceptable	to	patients	and	is	less	resource-intensive	than	standard	
current	practice	where	all	women	are	referred	for	genetic	counselling	prior	to	testing.	
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Tables	
	
Demographic	 n	
Mean	Age,	years	(range)	 64.3	(30-90)	
Country	of	Birth	
UK	 224	(97%)	
Other	 8	(3%)	
Ethnicity	
Caucasian	 226	(98%)	
Other	 6	(2%)	
Pathology	
Serous	 192	
Endometrioid	 20	
Adenocarcinoma	 15	
Mixed	 5	
Stage	
I	 34	
II	 6	
III	 137	
IV	 42	
Not	classified	 13	
Educational	Status	
(total	n=166)	
Degree	 25	(15%)	
Diploma	 37	(22%)	
Secondary	 100	(60%)	
	
	
Table	1	Study	population	demographics	
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Table	2	–	Age	at	diagnosis	and	pathology	characteristics	of	BRCA1/BRCA2	mutation	carriers		
	 	
	BRCA1/2+	(	n=	18)	 BRCA1/2	VUS	(	n=15)	 Non-BRCA1/2	(n=	199)	
Mean	Age	(	Range)	 49.5	(40-75)	 64.8	(41-84)	 66.1	(30-90)	
BRCA1	 12	(67%)	 3	(20%)	 N/A	
BRCA2	 6	(33%)	 12	(80%)	 N/A	
Pathology:	 	 	 	
High	grade	serous	 15	 11	 166	
Endometrioid	 1	 4	 15	
Adenocarcinoma	 2	 0	 13	
Mixed	types	 0	 0	 5	
Stage:	 	 	 	
I	 4	 5	 25	
II	 0	 0	 6	
III	 12	 9	 116	
IV	 2	 1	 39	
Not	classified	 0	 0	 13	
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Question	 n	
Mean	
Score	
SD	
Q1:	I	was	pleased	to	have	the	option	of	genetic	testing	
High	mean	score	=	pleased	to	have	option	of	genetic	test	 173	 5.72	 .846	
Q2:	I	had	access	to	enough	information	to	make	a	decision	about	testing	
High	mean	score	=	had	enough	information	to	make	decision	 174	 5.61	 .953	
Q3:	It	was	difficult	to	decide	whether	to	have	the	genetic	test	
	Low	mean	score	=	easy	to	make	decision	
172	 2.05	 1.80	
Q4:	I	had	enough	time	to	think	about	whether	to	have	the	genetic	test		
High	mean	score	=	had	enough	time	to	make	decision	
174	 5.43	 1.29	
Q5:	I	found	genetic	testing	to	be	useful	to	me		
High	mean	score	=	genetic	test	was	useful	
172	 5.49	 1.07	
Q6:		I	was	reassured	by	my	genetic	test	results	
High	mean	score	=	reassured	by	test	results	
173	 5.30	 1.30	
Q7:	The	genetic	test	results	allowed	me	to	better	understand	my	cancer	risks	
High	mean	score	=	test	allowed	better	understanding	of	cancer	risks	
173	 5.00	 1.48	
Q8:	The	genetic	test	results	allowed	me	to	better	understand	my	family’s	cancer	
risks	
High	mean	score	=	test	allowed	better	understanding	of	family’s	risk	
173	 5.31	 1.26	
Q9:	This	was	a	good	time	for	me	to	have	the	genetic	test	
High	mean	score	=	good	time	to	have	test	
171	 5.43	 1.19	
Q10:	I	would	have	preferred	to	wait	before	I	had	genetic	testing	
Low	mean	score	=	wouldn’t	have	wanted	to	wait	before	test	
171	 1.49	 1.21	
Q11:		I	found	genetic	testing	to	be	stressful	
Low	mean	score	=	didn’t	find	it	stressful	
170	 1.75	 1.53	
Q12:	I	was	satisfied	with	the	support	I	received	from	family	and	friends	
High	mean	score	=	satisfied	with	family	/	friend	support	
168	 5.52	 1.13	
Q13:	I	talked	to	my	family	about	my	genetic	test	
High	mean	score	=	most	talked	to	their	family	about	the	test	
169	 5.73	 1.15	
	
Table	3	–	Quantitative	analysis	of	acceptability	using	13	tailored	questions	
Possible	Score	range	was	1.0	(min)	to	6.0	(max)	
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		Figure	Legends	
	
	
	
	
Figure	1.	The	location	of	hospitals	in	the	Anglia	region	and	number	of	patients	recruited	at	each	site.	
Figure	2.		The	GTEOC	Testing	Protocol	
Figure	3.	Models	of	Service	delivery	for	Genetic	Testing	
	



	 1	
New	paradigms	for	BRCA1/BRCA2	testing	in	women	with	ovarian	cancer		–	results	of	the	Genetic	Testing	in	
Epithelial	Ovarian	Cancer	(GTEOC)	Study	
Supplementary	Files	
Resource	-	activity	 Unit	
cost	(£)	
Unit	description	 Source	of	data	
Existing	pathway	
Basic	 family	 history	 check	
in	Oncology	
19.28	 This	activity	involves	discussing	family	history	with	
the	 patient	 in	 order	 to	 determine	 whether	 the	
patient	is	potentially	eligible	for	genetic	testing	and	
therefore	referral	to	the	cancer	genetics	service	
Primary	 data	 collection	 at	
CUH	NHS	Foundation	Trust	
Referred	to	cancer	genetic	
service	(+ve	FH)	
65.03	 Patient	 is	 sent	 a	 letter	with	 FH	 form	 to	 return	 to	
cancer	 genetics	 service.	 FH	 form	 is	 received	 and	
checked	 and	 includes	 letter	 sent	 for	 appointment	
or	for	ineligibility	regarding	testing	
Primary	 data	 collection	 at	
CUH	NHS	Foundation	Trust	
Eligible	 for	 test,	 offered	
appointment	 and	 attends	
cancer	genetics	service	
434.47	 Patient	 attends	 45	 minute	 appointment	 with	
genetic	counsellor	(70%	led)	and	clinical	geneticist	
(30%	 led)	 to	provide	counselling	and	offer	genetic	
test	
NHS	 reference	 costs:	
financial	year	2014-2015	
Offered	 and	 accepts	
BRCA1/BRCA2	genetic	test	
850.00	 NHS	 test	 price	 at	 Addenbrooke’s	 Hospital.	 Test	
involves	sequencing	of	 the	entire	coding	region	of	
genes	plus	copy	number	analysis.	
UKGTN	website	
BRCA1/BRCA2	negative	 81.36	 Patient	 receives	 result	 as	 agreed	 during	
appointment	 either	 by	 letter	 (45%),	 phone	 call	
(45%)	or	face-to-face	appointment	(10%)	
Primary	 data	 collection	 at	
CUH	NHS	Foundation	Trust	
BRCA1/BRCA2	VUS	 81.36	 Patient	 receives	 result	 as	 agreed	 during	
appointment	 either	 by	 letter	 (45%),	 phone	 call	
(45%)	or	face-to-face	appointment	(10%)	–	same	as	
BRCA1/BRCA2	negative	
Primary	 data	 collection	 at	
CUH	NHS	Foundation	Trust	
BRCA1/BRCA2	positive	 95.09	 Patient	 receives	 result	 as	 agreed	 during	
appointment	either	by	letter	or	phone	call	(85%)	or	
by	face-to-face	appointment	(15%)	
Primary	 data	 collection	 at	
CUH	NHS	Foundation	Trust	
New	proposed	pathway	
Referred	to	cancer	genetic	
service	
47.28	 Patient	details	collected	by	genetic	counsellor	and	
processes	 eligibility	 for	 genetic	 testing	 over	 the	
phone	via	family	history	
Primary	 data	 collection	 at	
CUH	NHS	Foundation	Trust	
Eligible	 for	 test,	 offered	
appointment	 and	 attends	
cancer	genetics	service	
144.82	 Patient	 attends	 15	 minute	 appointment	 with	
genetic	counsellor	(70%	led)	and	clinical	geneticist	
(30%	 led)	 to	provide	counselling	and	offer	genetic	
NHS	 reference	 costs:	
financial	year	2014-2015	
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test	
Offered	 and	 accepts	
BRCA1/BRCA2	genetic	test	
850.00	 NHS	 test	 price	 at	 Addenbrooke’s	 Hospital.	 Test	
involves	sequencing	of	 the	entire	coding	region	of	
genes	plus	copy	number	analysis.	
UKGTN	website	
BRCA1/BRCA2	negative	 57.68	 Patient	receives	result	by	letter	 Primary	 data	 collection	 at	
CUH	NHS	Foundation	Trust	
BRCA1/BRCA2	VUS	 23.19	 Patient	 receives	 result	 by	 letter	 with	 20%	 of	
patients	 also	 receiving	 a	 phone	 call	 from	 genetic	
counsellor	
Primary	 data	 collection	 at	
CUH	NHS	Foundation	Trust	
BRCA1/BRCA2	positive	 385.82	 Patient	 received	 result	 by	 letter	 and	 an	
appointment	 is	 made	 for	 patients	 to	 attend	 and	
discuss	results	with	clinical	geneticist	
Primary	 data	 collection	 at	
CUH	NHS	Foundation	Trust	
	
	
Table	S1:	Estimated	resources,	test	unit	costs	and	assumptions	(2015)	
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Mutations	
ID	 Gene	 DNA	level	 Protein	level	 Age		
Cancer	
Pathology	 Grade	 Stage	 MS	 BOADICEA	
100	 BRCA1	 	c.325_3255dupGA		 	Leu1086fs		 54	 SP	 3	 4	 13		 3.2	
126	 BRCA1	 	c.2475delC		 	Asp825fs		 75	 SP	 3	 3c	 14		 1.4	
63	 BRCA1	 	c.4868C>G		 	Ala1623Gly		 67	 SP	 3	 3c	 20		 4.5	
185	 BRCA1	 	c.3307_3308insC		 	Cys1103Serfs*2		 40	 SP	 3	 3c	 25		 46.1	
8	 BRCA2	 	c.4154C>G		 	Ser1385Ter		 65	 SP	 3	 3	 24		 41.6	
218	 BRCA1	 	c.3193dupG		 	Asp1065fs		 55	 SP	 3	 3c	 25		 70.4	
134	 BRCA1	 	c.1961delA		 	Lys654fs		 52	 SP	 3	 3c	 23		 27.3	
17	 BRCA2	 	c.517-2A>G		
	
67	 SP	 3	 3	 22		 13.2	
40	 BRCA2	 	c.5247T>G		 	Tyr1749Ter		 65	 EC+	 3	 1c	 21		 7.1	
59	 BRCA1	 c.3756-59delGTCT		 	Ser1253fs		 54	 SP	 3	 3b	 21		 16.4	
14	 BRCA1	 	c.122A>G		 	His41Arg		 52	 SP	 3	 3c	 26		 2.1	
191	 BRCA2	 	c.6275_6276delTT		 	Leu2092fs		 68	 SP	 3	 3c	 11		 1.4	
137	 BRCA2	 	c.4154C>G		 	Ser1385Ter		 66	 SP	 3	 4	 11		 0.7	
90	 BRCA1	 	c.1360_1361delAG		 	Ser	454Ter		 59	 SP	 3	 1b	 26		 60.2	
168	 BRCA2	 	Het	del	ex14-16		
	
52	 SP	 3	 1c	 44		 89.1	
140	
214	
232	
BRCA1	
BRCA1	
BRCA1	
	c.2641G>T		
c.5153-26A>G	
c.4524G>A	
Glu881Ter		
	
Trp1508Ter	
49	
53	
45	
SP	
SP	
SP	
3	
3	
1	
3c	
3c	
1c	
21		
13	
13	
6.3	
5.5	
3.8	
	
VUS	
ID	 Gene	 DNA	level	 Protein	level	 Age		
Cancer	
Pathology	 Grade	 Stage	 MS	 BOADICEA	
19	 BRCA2	 	c.5278T>G		 	Ser1760Ala		 76	 SP	 3	 3c	 14		 4.4	
31	 BRCA2	 	c.4068G>A		 	Leu1356Leu		 70	 SP	 3	 4	 10		 0.3	
102	 BRCA2	 	c.8072C>T		 	Ser2691Phe		 51	 SP	 3	 3c	 15		 1.8	
101	 BRCA2	 	c.8111C>T		 	Ser2704Phe		 67	 SP	 3	 3c	 18		 11.8	
162	 BRCA2	 	c.6403A>C		 	Asn2135His		 68	 SP	 3	 3b	 10		 0.9	
215	 BRCA1	 	c.1534C>T		 	Leu512Phe		 52	 EC	 1	 1a	 13		 6.8	
54	 BRCA2	 	c.1798T>C		 	Tyr600His		 72	 SP	 3	 3c	 11		 0.8	
		 BRCA2										c.1909+8_1909+9delTG	at	the	extron10/intron10	boundary		
	 	
		
		 BRCA2	 	c.7504C>T		 	Arg2502Cys		
	 	 	 	 	
		
166	 BRCA2	 	c.506A>G		 	Lys169Arg		 72	 SP	 3	 1c	 10		 0.5	
176	 BRCA2	 	c.1460C>A		 	Ala487Glu		 41	 SP	 3	 3c	 21		 28.4	
111	 BRCA2	 	c.8905G>A		 	Val2969Met		 83	 SP	 3	 3c	 10		 0.1	
150	 BRCA1	 	c.1534C>T		 	Leu512Phe		 72	 SP	 3	 3c	 10		 0.6	
20	 BRCA2	 	c.68-7T>A		
	
74	 SP	 3	 3c	 10		 0.7	
1	 BRCA1	 	c.1563A>G		 	Ala521Ala		 55	 EC	 1	 1a	 14		 4.1	
28	
223	
BRCA2	
BRCA2	
	c.223G>C		
	c.967G>T	
	Ala75Pro		
	Val323Leu	
70	
64	
EC	
EC	
3	
2	
1c	
1c	
30	
	10	
4.4	
2.5	
	
Table	S2.	BRCA1/BRCA2	Mutations	and	VUS	identified	in	the	study	
+=	High	grade	adenocarcinoma	with	features	in	favour	of	a	grade	3	endometrioid	adenocarcinoma			 	
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	 Current	patient	testing	pathway	(£)	 GTEOC	patient	testing	pathway	(£)	
Budget	 Average	cost	
per	BRCA	
positive	
Average	cost	
per	test	
offered	
Budget	 Average	cost	
per	BRCA	
positive	
Average	cost	
per	test	
offered	
Base	case,	£850,	50%	 142,702	 11,892	 2,265	 253,617	 14,919	 1,093	
Cost	of	test	
	 £650	 130,102	 10,842	 2,065	 207,217	 12,189	 893	
	 £499	 120,589	 10,049	 1,914	 172,185	 10,129	 742	
	 £350	 111,202	 9,267	 1,765	 137,617	 8,095	 593	
	 £190	 101,122	 8,427	 1,605	 100,497	 5,912	 433	
Percentage	referral	
	 0%	 105,772	 8,814	 1,679	 253,617	 14,919	 1,093	
	 25%	 124,454	 10,371	 1,975	 253,617	 14,853	 1,093	
	 75%	 160,950	 13,412	 2,554	 253,617	 14,853	 1,093	
	 100%	 179,197	 14,933	 2,844	 253,617	 14,853	 1,093	
GTEOC	age	cut-off	<70	
£850,	
50%	
	 142,702	 11,892	 2,265	 148,429	 9,895	 1,091	
Scenario	
£650,	50%,	<70	age	 130,102	 10,842	 2,065	 121,229	 8,082	 891	
	
Table	 S3:	 Base	 case	 analysis	 results	 plus	 sensitivity	 analysis	 of	 patient	 testing	 pathway	 budget,	
average	patient	pathway	cost	of	BRCA	positive,	and	average	patient	pathway	cost	per	genetic	 test	
offered	 for	 the	 232	 women	 eligible	 for	 the	 GTEOC	 study.	 In	 the	 GTEOC	 testing	 pathway	 all	 the	
patients	were	given	the	genetic	test.	The	budget	is	the	overall	cost	of	all	patients	receiving	eligibility	
checks,	counselling	and	genetic	testing	plus	post-test	work-up	i.e.,	the	average	cost	per	test	offered	is	
the	 total	 budget	 divided	 by	 the	 number	 of	 tests	 offered	 which	 is	 232.	 For	 the	 current	 testing	
pathway,	we	calculated	the	Manchester	score	for	all	patients	and	based	on	this,	63	patients	would	
have	been	eligible	 for	genetic	 testing	and	offered	the	test.	For	these	patients	the	full	work-up	cost	
was	 calculated	 from	 eligibility	 check	 to	 test	 and	 post-test	 work-up.	 For	 the	 base	 case	 we	 then	
assumed	 that	 50%	 of	 the	 remaining	 169	 patients	 would	 have	 still	 been	 referred	 for	 genetic	 test	
counselling	and	so	would	incur	those	costs.	We	calculated	for	these	84	patients	the	cost	of	eligibility	
and	genetic	counselling	but	did	not	include	test	costs	as	these	patients	did	not	meet	test	criteria.	For	
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the	remaining	85	patients	we	only	included	the	cost	of	checking	eligibility	for	the	referral.	The	sum	of	
these	three	sets	of	costs	for	the	232	patients	equal	the	budget	and	the	average	cost	per	test	offered	
is	 that	 budget	 divided	 by	 the	 number	 of	 tests	 offered	 (i.e.,	 total	 budget	 divided	 by	 63).		
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Figure	S1:	Patient	pathway	for	the	current	provision	of	BRCA1/BRCA2	testing	in	epithelial	ovarian	cancer	patients	
Eligible	for	test,	offered	appointment	and	attends	cancer	genetic	service Eligible	for	test	but	rejects	cancer	genetics	service	appointment 
Affected	individual	with	epithelial	ovarian	cancer 
Basic	family	history	check	in	Oncology 
Referred	to	cancer	genetics	service (+ve	FH) 
Offered	but	declines	BRCA1/BRCA2	genetic	test Offered	and	accepts	BRCA1/BRCA2	genetic	test 
BRCA1/BRCA2	negative BRCA1/BRCA2	VUS BRCA1/BRCA2	positive 
Not	eligible	for	BRCA1/BRCA2	genetic	testing 
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Figure	S2:	Proposed	patient	pathway	for	the	provision	of	BRCA1/BRCA2	testing	in	epithelial	ovarian	cancer	patients	from	the	GTEOC	study.	
	
Affected	individual	with	epithelial	ovarian	cancer 
Referred	to	cancer	genetics	service 
Eligible	for	test,	offered	appointment	and	attends	cancer	genetics	service Eligible	for	test	but	rejects	cancer	genetics	service	appointment 
Offered	but	declines	BRCA1/BRCA2	genetic	test Offered	and	accepts	BRCA1/BRCA2	genetic	test 
BRCA1/BRCA2	negative BRCA1/BRCA2	VUS BRCA1/BRCA2	positive 
Not	eligible	for	BRCA1/BRCA2	genetic	testing 
